Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report) hit a new 52-week low during trading on Thursday . The stock traded as low as $13.08 and last traded at $13.11, with a volume of 294162 shares changing hands. The stock had previously closed at $13.23.
Takeda Pharmaceutical Trading Down 1.2 %
The firm has a market cap of $41.35 billion, a P/E ratio of 19.80, a PEG ratio of 3.79 and a beta of 0.53. The company has a 50 day moving average of $14.09 and a 200 day moving average of $14.21. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.55 and a current ratio of 1.06.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings results on Thursday, February 1st. The company reported $0.51 EPS for the quarter. The business had revenue of $7.52 billion during the quarter. Takeda Pharmaceutical had a return on equity of 12.57% and a net margin of 6.90%. Analysts predict that Takeda Pharmaceutical Company Limited will post 1.5 EPS for the current fiscal year.
Institutional Investors Weigh In On Takeda Pharmaceutical
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rise Advisors LLC acquired a new stake in Takeda Pharmaceutical in the 1st quarter worth approximately $26,000. GAMMA Investing LLC acquired a new position in shares of Takeda Pharmaceutical during the fourth quarter worth approximately $28,000. Principal Securities Inc. acquired a new position in shares of Takeda Pharmaceutical during the fourth quarter worth approximately $28,000. First United Bank & Trust acquired a new position in shares of Takeda Pharmaceutical during the fourth quarter worth approximately $29,000. Finally, Lindbrook Capital LLC lifted its holdings in shares of Takeda Pharmaceutical by 40.6% during the fourth quarter. Lindbrook Capital LLC now owns 4,065 shares of the company's stock worth $58,000 after buying an additional 1,174 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.
About Takeda Pharmaceutical
(
Get Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Read More
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
